Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Clinical intervals and diagnostic characteristics in a cohort of prostate cancer patients in Spain, a multicentre observational study

  • Bonfill, X. (Xavier)|||0000-0003-1530-3509
  • Martinez-Zapata, Mª José|||0000-0002-5836-1138
  • Vernooij, Robin W. M.|||0000-0001-5734-4566
  • Sánchez Pérez, María José|||0000-0003-4817-0757
  • Suárez Varela, María Morales
  • De la Cruz, Javier|||0000-0002-2010-4128
  • Emparanza, José Ignacio
  • Ferrer Forés, Maria Montserrat|||0000-0001-9867-7391
  • Pijoán, José Ignacio
  • Ramos Goñi, Juan Manuel
  • Palou, Juan|||0000-0003-1264-5327
  • Schmidt, Stefanie
  • Abraira, Víctor|||0000-0002-4615-8503
  • Zamora, Javier|||0000-0003-4901-588X
Little is known about the healthcare process for patients with prostate cancer, mainly because hospital-based data are not routinely published. The main objective of this study was to determine the clinical characteristics of prostate cancer patients, the, diagnostic process and the factors that might influence intervals from consultation to diagnosis and from diagnosis to treatment. We conducted a multicentre, cohort study in seven hospitals in Spain. Patients' characteristics and diagnostic and therapeutic variables were obtained from hospital records and patients' structured interviews from October 2010 to September 2011. We used a multilevel logistic regression model to examine the association between patient care intervals and various variables influencing these intervals (age, BMI, educational level, ECOG, first specialist consultation, tumour stage, PSA, Gleason score, and presence of symptoms) and calculated the odds ratio (OR) and the interquartile range (IQR). To estimate the random inter-hospital variability, we used the median odds ratio (MOR). 470 patients with prostate cancer were included. Mean age was 67.8 (SD: 7.6) years and 75.4 % were physically active. Tumour size was classified as T1 in 41.0 % and as T2 in 40 % of patients, their median Gleason score was 6.0 (IQR:1.0), and 36.1 % had low risk cancer according to the D'Amico classification. The median interval between first consultation and diagnosis was 89 days (IQR:123.5) with no statistically significant variability between centres. Presence of symptoms was associated with a significantly longer interval between first consultation and diagnosis than no symptoms (OR:1.93, 95%CI 1.29-2.89). The median time between diagnosis and first treatment (therapeutic interval) was 75.0 days (IQR:78.0) and significant variability between centres was found (MOR:2.16, 95%CI 1.45-4.87). This interval was shorter in patients with a high PSA value (p = 0.012) and a high Gleason score (p = 0.026). Most incident prostate cancer patients in Spain are diagnosed at an early stage of an adenocarcinoma. The period to complete the diagnostic process is approximately three months whereas the therapeutic intervals vary among centres and are shorter for patients with a worse prognosis. The presence of prostatic symptoms, PSA level, and Gleason score influence all the clinical intervals differently.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Clinical interval and diagnostic characteristics in a cohort of bladder cancer patients in Spain, a multicenter observational study

  • Bonfill, X. (Xavier)|||0000-0003-1530-3509
  • Martinez-Zapata, Mª José|||0000-0002-5836-1138
  • Vernooij, Robin W. M.|||0000-0001-5734-4566
  • Sánchez Pérez, María José|||0000-0003-4817-0757
  • Suárez-Varela, María Morales
  • De la Cruz, Javier|||0000-0002-2010-4128
  • Emparanza, José Ignacio
  • Ferrer Forés, Maria Montserrat|||0000-0001-9867-7391
  • Pijoan, José Ignacio
  • Palou, Juan|||0000-0003-1264-5327
  • Schmidt, Stefanie
  • Madrid, Eva|||0000-0002-8095-5549
  • Abraira, Víctor|||0000-0002-4615-8503
  • Zamora, Javier|||0000-0003-4901-588X
We performed a cohort study in seven hospitals in Spain to determine the clinical characteristics of incident patients with bladder cancer, the diagnostic process, and the conditions that might affect health care interval times. 314 patients with bladder cancer were included, 70.3 (Standard Deviation [SD] 11.2) years old and 85.0% male. Clinical stage was T1 in 45.9% of patients. The median interval time between first consultation and diagnosis was of 104.0 days (Inter quartile range [IQR]:112.0; range from 0 to 986), being shorter for those patients who attended a hospital for their first consultation. The median interval time between diagnosis and first treatment was of 0.0 days (IQR: 0.0; range from 0 to 366), being longer when the patient had a pathologic tumor stage ≥ T2a. The online version of this article (10.1186/s13104-017-3024-8) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Bladder cancer index, Cross-cultural adaptation into Spanish and psychometric evaluation

  • Schmidt, Stefanie
  • Riel, Ricard
  • Frances, Albert
  • Lorente Garín, José Antonio
  • Bonfill, X. (Xavier)|||0000-0003-1530-3509
  • Martinez-Zapata, Mª José|||0000-0002-5836-1138
  • Morales Suárez-Varela, María
  • De la Cruz, Javier|||0000-0002-2010-4128
  • Emparanza, José Ignacio
  • Sánchez Pérez, María José|||0000-0003-4817-0757
  • Zamora, Javier|||0000-0003-4901-588X
  • Ramos Goñi, Juan Manuel
  • Alonso, Jordi|||0000-0001-8627-9636
  • Ferrer Forés, Maria Montserrat|||0000-0001-9867-7391
  • Becerra, Virginia|||0000-0002-8811-3899
  • Pardo Cladellas, Yolanda|||0000-0003-4982-5495
  • Garin, Olatz|||0000-0001-6193-0779
  • Orrego, Carola|||0000-0002-2978-6268
  • Suñol Sala, Rosa|||0000-0003-1902-833X
  • Osorio, Dimelza|||0000-0001-6166-647X
  • Cánovas, Esther
  • Sancho-Pardo, Gemma|||0000-0003-2266-6172
  • Bolívar, Ignasi
  • Bachs, Jordi
  • Maroto Rey, Pablo|||0000-0002-0030-0412
  • Quintana Ruiz, Maria Jesús|||0000-0002-1055-9786
  • Martín-Lorente, Cristina|||0000-0002-9827-0521
  • Algaba, Ferran|||0000-0002-0071-4164
  • Palou, Juan|||0000-0003-1264-5327
  • Esquena Fernández, Salvador
  • Vernooij, Robin W. M.|||0000-0001-5734-4566
  • Martínez, Arnaia
  • Pijoan Zubizarreta, José Ignacio|||0000-0002-5974-5280
  • Martínez, Lorea G.
  • Castro Díaz, David|||0000-0002-4484-9159
  • López Bastida, Julio|||0000-0002-9354-751X
  • Suárez Pacheco, Armando
  • García López, César
  • Cózar Olmo, José Manuel
  • Martínez García, Carmen
  • Chan, Daisy Chang
  • Sánchez Pérez, María José|||0000-0003-4817-0757
  • Díaz Moratinos, Ana Isabel
  • Montero, Ángel|||0000-0001-5566-0493
  • Hervás Morón, Asunción|||0000-0002-7439-1820
  • Vallejo Ocaña, Carmen
  • Varona, Constantino
  • Burgos-Revilla, Javier
  • Polo Rubio, Jose Alfredo
  • López-Fando, Luís|||0000-0002-2881-1329
  • Jiménez-Cidre, Miguel Ángel|||0000-0002-9911-8054
  • Muriel García, Alfonso
  • Plana, Maria Nieves|||0000-0003-0921-7954
  • Morera López, Rosa María
  • Sancho García, Sonsoles
  • Abraira, Víctor|||0000-0002-4615-8503
  • Gómez Dos Santos, Victoria
  • Gómez de la Cámara, Agustín
  • Passas Martínez, Juan
  • García Muñoz, Humberto
  • Cabeza Rodríguez, María Ángeles
  • Ruíz Díaz, Irune
  • Sanz-Jaka, Juan Pablo Pedro
  • Velásquez, M. José
  • Llopis González, Agustín|||0000-0001-8701-6918
  • Morales, María
  • Camps, Carlos|||0000-0002-0648-5403
  • Caballero Díaz, Cristina
  • Marqués Vidal, Emilio
  • Sánchez Ballester, Francisco
  • Juan-Escudero, Joaquín Ulises
  • Pastor Peidro, Jorge
  • López-Torrecilla, José Luis
  • Ramos de Campos, Macarena
  • Martorell Cebollada, Miguel
Background: The Bladder Cancer Index (BCI) is so far the only instrument applicable across all bladder cancer patients, independent of tumor infiltration or treatment applied. We developed a Spanish version of the BCI, and assessed its acceptability and metric properties. Methods: For the adaptation into Spanish we used the forward and back-translation method, expert panels, and cognitive debriefing patient interviews. For the assessment of metric properties we used data from 197 bladder cancer patients from a multi-center prospective study. The Spanish BCI and the SF-36 Health Survey were self-administered before and 12 months after treatment. Reliability was estimated by Cronbach's alpha. Construct validity was assessed through the multi-trait multi-method matrix. The magnitude of change was quantified by effect sizes to assess responsiveness. Results: Reliability coefficients ranged 0.75-0.97. The validity analysis confirmed moderate associations between the BCI function and bother subscales for urinary (r = 0.61) and bowel (r = 0.53) domains; conceptual independence among all BCI domains (r ≤ 0.3); and low correlation coefficients with the SF-36 scores, ranging 0.14-0.48. Among patients reporting global improvement at follow-up, pre-post treatment changes were statistically significant for the urinary domain and urinary bother subscale, with effect sizes of 0.38 and 0.53. Conclusions: The Spanish BCI is well accepted, reliable, valid, responsive, and similar in performance compared to the original instrument. These findings support its use, both in Spanish and international studies, as a valuable and comprehensive tool for assessing quality of life across a wide range of bladder cancer patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Follow-up care over 12months of patients with prostate cancer in Spain A multicenter prospective cohort study

  • Bonfill, X. (Xavier)|||0000-0003-1530-3509
  • Martinez-Zapata, Mª José|||0000-0002-5836-1138
  • Vernooij, Robin W. M.|||0000-0001-5734-4566
  • Sánchez Pérez, María José|||0000-0003-4817-0757
  • Morales-Suárez-Varela, María|||0000-0003-0785-1492
  • Emparanza, José Ignacio
  • Ferrer Forés, Maria Montserrat|||0000-0001-9867-7391
  • Pijoan, José Ignacio
  • Palou, Juan|||0000-0003-1264-5327
  • Madrid, Eva|||0000-0002-8095-5549
  • Abraira, Víctor|||0000-0002-4615-8503
  • Zamora, Javier|||0000-0003-4901-588X
The therapeutic approach is crucial to prostate cancer prognosis. We describe treatments and outcomes for a Spanish cohort of patients with prostate cancer during the first 12 months after diagnosis and identify the factors that influenced the treatment they received. This multicenter prospective cohort study included patients with prostate cancer followed up for 12 months after diagnosis. Treatment was stratified by factors such as hospital, age group (<70 and ≥70 years), and D'Amico cancer risk classification. The outcomes were Eastern Cooperative Oncology Group (ECOG) performance status, adverse events (AEs), and mortality. The patient characteristics associated with the different treatment modalities were analyzed using multivariate logistic regression. We included 470 men from 7 Spanish tertiary hospitals (mean (standard deviation) age 67.8 (7.6) years), 373 (79.4%) of which received treatment (alone or in combination) as follows: surgery (n = 163; 34.7%); radiotherapy (RT) (n = 149; 31.7%); and hormone therapy (HT) (n = 142; 30.2%). The remaining patients (n = 97) were allocated to no treatment, that is, watchful waiting (14.0%) or active surveillance (5.7%). HT was the most frequently administered treatment during follow-up and RT plus HT was the most common therapeutic combination. Surgery was more frequent in patients aged <70, with lower histologic tumor grades, Gleason scores <7, and lower prostate-specific antigen levels; while RT was more frequent in patients aged ≥70 with histologic tumor grade 4, and higher ECOG scores. HT was more frequent in patients aged ≥70, with histologic tumor grades 3 to 4, Gleason score ≥8, ECOG ≥1, and higher prostate-specific antigen levels. The number of fully active patients (ECOG score 0) decreased significantly during follow-up, from 75.3% at diagnosis to 65.1% at 12 months (P <.001); 230 (48.9%) patients had at least 1 AE, and 12 (2.6%) patients died. Surgery or RT were the main curative options. A fifth of the patients received no treatment. Palliative HT was more frequently administered to older patients with higher tumor grades and higher Gleason scores. Close to half of the patients experienced an AE related to their treatment.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Follow-up care of 12 months of patients with bladder cancer in Spain, A multicenter prospective cohort study

  • Bonfill, X. (Xavier)|||0000-0003-1530-3509
  • Martinez-Zapata, Mª José|||0000-0002-5836-1138
  • Barrionuevo-Rosas, Leslie
  • Vernooij, Robin W. M.|||0000-0001-5734-4566
  • Sánchez Pérez, María José|||0000-0003-4817-0757
  • Morales-Suárez-Varela, María|||0000-0003-0785-1492
  • De la Cruz, Javier|||0000-0002-2010-4128
  • Emparanza, José Ignacio
  • Ferrer Forés, Maria Montserrat|||0000-0001-9867-7391
  • Pijoan, José Ignacio
  • Palou, Juan|||0000-0003-1264-5327
  • Frances, Albert
  • Madrid, Eva|||0000-0002-8095-5549
  • Coscia, Claudia
  • Zamora, Javier|||0000-0003-4901-588X
The therapeutic approach of bladder cancer strongly determines its prognosis. We describe the treatments and outcomes for a Spanish cohort of patients with bladder cancer for the first 12 months after diagnosis and identify the factors that influenced the decision to undergo the treatment received. We conducted a multicenter, prospective, cohort study including primary bladder cancer patients during the first 12 months after diagnosis. The clinical outcomes were performance status (ECOG), adverse events and any cause of mortality. We stratified the analysis by factors that might influence the treatments received. We conducted univariate and multivariable logistic regression models to assess which patient and tumor characteristics were associated with receiving adjuvant treatment in the subgroup of noninvasive bladder cancer patients. In total, 314 patients were included (85% men; 53.8%.